ArticlesAssociation of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
Introduction
Prostate cancer is a very common disease in more-developed countries: more than 39200 men died of the disease in the USA in 1998,1 and 50122 died in the European Union in 1990.2 Prostate cancer is androgen dependent,3, 4 and we have previously proposed that variations in androgen metabolism may affect a man's risk of this disease.4, 6 We have provided evidence that increased intraprostatic androgen metabolism, particularly through the enzyme steroid 5α-reductase, may have an important role in predisposition to prostate cancer. This enzyme catalyses the conversion of testosterone to dihydrotestosterone-the most potent androgen in the prostate. Thus, genetic variants encoded by the steroid 5α-reductase gene (SRD5A2) may have an effect on predisposition to prostate cancer. We report our epidemiological and biochemical findings on the relation between prostate cancer and a constitutional (germline) mis-sense substitution in SRD5A2, which results in the replacement of an alanine residue at codon 49 with threonine (A49T).7 This substitution is associated with a significantly increased risk of prostate cancer (particularly of an advanced nature), probably through increased metabolic activation of testosterone to dihydrotestosterone.
Section snippets
Epidemiology
This case-control study was part of the prospective Hawaii-Los Angeles Multiethnic Cohort Study of Diet and Cancer, which has been described in detail elsewhere.8 About 200000 African-American, Japanese-American, Hispanic, and white individuals between the ages of 45 and 75 years are being followed up for incident cancer diagnoses, primarily through linkage with the population-based Surveillance, Epidemiology and End Results cancer registries for Hawaii and Los Angeles County, USA. Data on
Results
The mean age of the controls was 63·6 years, compared with 68·9 years for the cases. The cases and controls did not differ with respect to education level. The racial/ethnic distribution of the study population is presented in table 1.
The A49T mis-sense substitution was uncommon in healthy African-American and Hispanic men in Los Angeles: we found an allele frequency of 1·0% (five of 522) in African-American controls and 2·3% (nine of 400) in Hispanic controls (table 2).
In African-American men
Discussion
We have investigated the relation between three polymorphisms in the SRD5A2 gene and risk of prostate cancer in the cohort described. The first, a (TA)n dinucleotide repeat in the 3′ untranslated region,16 was originally described by Davis and Russell.17 We found differences in the distribution of (TA)n alleles in different racial/ethnic control groups,16 and preliminary case-control study results suggested a weak association between long repeats and risk of prostate cancer. However, we have
References (24)
- et al.
Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990
Eur J Cancer
(1997) - et al.
5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males
Lancet
(1992) - et al.
Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25
Am J Hum Genet
(1997) - et al.
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42·2-43
Am J Hum Genet
(1998) - et al.
Cancer statistics, 1998
CA Cancer J Clin
(1998) - et al.
Studies on prostatic cancer
Cancer Res
(1941) - et al.
Endogenous hormones as a major factor in human cancer
Cancer Res
(1982) - et al.
Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility
Cancer Res
(1998) - et al.
A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase
Cancer Res
(1997) - Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics....
The diagnosis and treatment of prostate cancer
Annu Rev Med
Staging systems and prognostic factors for prostate cancer
Cited by (249)
In silico and functional studies reveal novel loss-of-function variants of SRD5A2, but no variants explaining excess 5α-reductase activity
2019, Journal of Steroid Biochemistry and Molecular BiologyReflections of a Biomedical Scientist on Four Continents in Interdisciplinary Research
2018, Trends in GeneticsRace/ethnicity and criminal behavior: Neurohormonal influences
2017, Journal of Criminal JusticeProstate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer
2017, Urologic Oncology: Seminars and Original InvestigationsAndrogen Regulation of Neural Circuit Activity: Molecules and Mechanisms
2017, Hormones, Brain and Behavior: Third Edition